Abstract | GERD is a common condition worldwide. Key mechanisms of disease include abnormal oesophagogastric junction structure and function, and impaired oesophageal clearance. A therapeutic trial of acid-suppressive PPI therapy is often the initial management, with endoscopy performed in the setting of alarm symptoms and to exclude other conditions. If symptoms persist and endoscopy does not reveal evidence of GERD, oesophageal function tests are performed, including oesophageal manometry and ambulatory reflux monitoring. However, reflux episodes can be physiological, and some findings on endoscopy and manometry can be encountered in asymptomatic individuals without GERD symptoms. The diagnosis of GERD on the basis of functional oesophageal testing has been previously reported, but no updated expert recommendations on indications and the interpretation of oesophageal function testing in GERD has been made since the Porto consensus over a decade ago. In this Consensus Statement, we aim to describe modern oesophageal physiological tests and their analysis with an emphasis on establishing indications and consensus on interpretation parameters of oesophageal function testing for the evaluation of GERD in clinical practice. This document reflects the collective conclusions of the international GERD working group, incorporating existing data with expert consensus opinion. NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY VOLUME 14 | NOVEMBER 2017 | 665 CONSENSUS STATEMENT © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .
GERD consists of troublesome symptom s or mucosal damage resulting from retrograde movement of gastric content through an incompetent oesophagogastric junc tion (EGJ) 1 . GERD is one of the most common gastro intestinal ailments worldwide; up to 40% of the US population report oesophageal symptoms intermittently and 10-20% have at least weekly symptoms 2, 3 . Typical GERD symptoms consist of heartburn and regurgitation, and clinical diagnosis is made on the basis of typical symptoms, supported by symptom response from empiric PPI therapy 4, 5 . Alarm symptoms (for example, dysphagia, weight loss, anaemia), atypical presentations (including chest pain, laryngeal symp toms) or lack of response to empiric therapy prompt further evaluation with an upper endoscopy (EGD; oesophagogastroduodenoscopy) 4, 6 . If symptoms per sist despite empiric therapy, and EGD does not reveal evidence of GERD (oesophagitis, peptic oesophageal stricture, Barrett mucosa), oesophageal function tests are performed, including oesophageal manometry and ambulatory reflux monitoring 7 . However, reflux episodes can be physiological, and some findings on endoscopy (Los Angeles (LA) classification grade A or B reflux oesophagitis 8 ) and manometry (hypotensive EGJ, ineffective oesophageal manometry) can be encoun tered in asymptomatic individuals without GERD symptoms 9 . GERD diagnostic criteria on the basis of oesophageal testing have been previously reported 7, [10] [11] [12] ; however, no updated consensus on indications and interpretation of oesophageal function testing in GERD among experts in the field has been made since the 2004 Porto consensus 13 . Under the auspices of the International Working Group for Disorders of Gastrointestinal Motility and Function (www.idigest.ch), the authors of this manu script organized a consensus project to describe modern oesophageal physiological tests and their analysis. The aim of this consensus project was to obtain 'a standard of practice' for clinicians and motility laboratories world wide, and to reorganize and reiterate existing know ledge regarding GERD evaluation, as it has been over a decade since the last consensus of its kind in Porto 13 . Throughout this process, emphasis was focused on establishing indications and agreeing on interpretation of oesophageal function testing for the evaluation of GERD in clinical practice. This Consensus Statement reflects the collective clinical conclusions of the interna tional GERD working group evaluating modern GERD testing and interpretation, incorporating existing data with expert consensus opinion. Novel concepts and recommendations developed through this process are shown in BOX 1 and will be further discussed throughout.
Methods
The GERD consensus steering committee (S.R., C.P.G., E.S., A.B.) was appointed by the International Working Group for Disorders of Gastrointestinal Motility and Function. Under the guidance of the steering commit tee, an international GERD working group performed focused literature searches using search terms pertaining to GERD (for example, "GERD testing", "GERD diagno sis", "ambulatory pH" and "pHimpedance monitoring", "hiatus hernia", "transient lower oesophageal sphincter (LES) relaxation", "oesophageal dysmotility", "oesopha geal manometry", "endoscopy", "GERD phenotypes") to identify pertinent statements relating to oesophageal pathophysiology and oesophageal function testing in the context of GERD. At consensus meetings attended by international GERD experts held in conjunction with international conferences (United European Gastro enterology week 2015-2017, Digestive Disease Week 2015-2016, Ascona II 2015), these statements were extensively discussed and debated. Consensus was achieved through careful evaluation using the GRADE concept 14 to define the quality of the supporting evidence based on study design, study limitations, consistency, directness, precision, publication bias, other modifying factors and expert agreement when guidelines lacked supporting evidence.
Mechanisms of gastro-oesophageal reflux
Oesophagogastric junction barrier. An ineffective EGJ barrier is consistently present in GERD (FIG. 1) , often combined with morphological abnormality (hiatus hernia). Transient lower oesophageal sphincter relax ation (TLESR) is a physiological response to gastric distension, and excessive reflux during TLESRs is the most common EGJ event seen in patients with GERD 15 . Modern highresolution manometry (HRM) criteria for TLESRs include profound EGJ relaxation of >10 s in the absence of swallowing, with inhibition of crural diaphragm contraction 16 . TLESRs are not routinely evalu ated on oesophageal HRM, although they do affect oesophageal reflux burden. By contrast, motor deficiency and abnormal morphology of the EGJ barrier are readily identified on HRM.
An intact EGJ barrier consists of superimposed LES and crural diaphragm, with adequate resting tone pre venting retrograde migration of gastric content at rest (FIG. 1) . EGJ morphology is characterized into three morphological subtypes: subtype 1 (normal), subtype 2 (<3 cm separation between LES and crural diaphragm) and subtype 3 (≥3 cm separation between LES and crural diaphragm) 17 . The intrinsic LES can independently have a low resting tone, with values <5 mmHg during the end expiratory phase being considered abnormal 12 . Inspiratory crural diaphragm augmentation provides adjunctive EGJ barrier function when intrathoracic pressures are at their lowest 18, 19 ; this phenomenon is an important element not wellassessed by basal and end expiratory LES pressure measurements. The EGJ contractile integral might overcome these drawbacks by combining EGJ anatomy, basal tone and variation with respiration into a single metric, calculated using an algor ithm similar to the distal contractile integral that takes into account the length and vigour of the EGJ resting barrier function and corrected for respiratory vari ation 20, 21 . Normative EGJ contractile integral values have been described and available data suggest reflux burden might be abnormal in the setting of a low EGJ contractile integral [21] [22] [23] . Thus, an abnormal EGJ barrier can be hypotensive (with reduced resting tone that can be overcome by increased intraabdominal pressure), disrupted with separation of the two components of the EGJ barrier (hiatus hernia) or both. In the presence of a hiatus hernia, the resting tone of the intrinsic LES is typi cally hypotensive, with oesophageal reflux burden higher than with either abnormality alone 24 . Consequently, these two EGJ abnormalities can coexist and both can contribute to abnormal reflux burden.
Box 1 | Key advances in the clinical approach to GERD
• The concept of proven GERD, with prior endoscopic or physiological evidence of disease, versus unproven GERD is utilized to direct which oesophageal reflux monitoring study to use and whether it should be performed on or off acid suppressive therapy • Consensus definitions of thresholds for pH and pH-impedance monitoring have been made in defining physiological and pathophysiological reflux measurements, including an inconclusive 'grey area' that requires further evidence to confirm a diagnosis of GERD • Acid exposure time is physiological when <4% and pathological when >6%; values in between are considered borderline, requiring additional clinical or physiological evidence to confirm or refute a GERD diagnosis • When the diagnosis is inconclusive on reflux monitoring alone, the use of additional features are suggested, including histology, new pH-impedance metrics and high-resolution manometry • A new classification of oesophageal contractility and oesophagogastric junction motor findings in GERD is made, incorporating data obtained by high-resolution manometry
Oesophageal hypomotility. When a reflux episode occurs, the refluxate is cleared by a combination of a second ary peristaltic contraction and a primary post reflux swallowinduced peristaltic contraction that also brings saliva to neutralize oesophageal mucosal acidifi cation 25 . In many patients with GERD, oesophageal motor function is intact and normal 26 ; however, hypomo tility can contribute to delayed oesophageal clearance and increases the likelihood of oesophagitis [27] [28] [29] . The spec trum of hypomotility consists of fragmented peristalsis, ineffective oesophageal motility and absent contractility, with increased prevalence of abnormal oesophageal bolus clearance towards the high end of this spectrum [30] [31] [32] .
Refluxate. The acid pocket is a supernatant layer of gastric acid overlying an ingested meal immediately below the EGJ. In health, the transition from an acid to alkaline milieu occurs at the EGJ in the post prandial period 33 . However, when the EGJ barrier is weak or disrupted, for example in presence of hiatus hernia, the acid pocket can migrate into the distal oesophagus, leading to pathological acid in the distal oesophagus 34 . Delayed gastric emptying and acid hypersecretory states, such as in gastrinsecreting tumours (gastrino mas), are additional downstream factors that contribute to oesophageal reflux burden 35 . Acid and other compo nents of the refluxate (pepsin, bile acid) can participate in mucosal damage and in complications including Barrett metaplasia 36 . Finally, the degree of proximal migration of the refluxate and differences in oesophageal perception of reflux (sensitivity) between individuals can contrib ute to symptom reporting in GERD 37 . Symptoms identical to typical GERD can be reported with reflux hypersensitivity and functional heartburn, in which oesophageal reflux burden is physiological; both can overlap with true GERD when symptoms persist despite reflux burden being rendered physiological with acidsuppressive therapy 38 .
Oesophageal manometry in GERD The pathophysiology of GERD does not have a direct implication on initial GERD management, as treat ment consists of acid suppression. However, if GERD symptoms persist despite empiric therapy and endo scopy is normal, further oesophageal testing is recom mended
. Manometry is commonly performed for position ing of pH or pHimpedance catheters. When symptoms persist, manometry is also performed to exclude acha lasia and alternate disorders that can mimic GERD, such as rumination, systemic sclerosis and supragastric belching 26, 39 . Consequently, under standing motor mechanisms of GERD and identifying conditions mimicking GERD complement information obtained from ambulatory oesophageal reflux monitor ing in planning manage ment (TABLE 1) . However, the Chicago Classification of oesophageal motor disorders targets abnormal bolus transit with symptomatic dys phagia and chest pain, but was not designed to assess motor function in the context of GERD 40 . Thus, the proposed classification, devised by this international GERD working group and detailed in the following sub sections, represents an advance to previous classifi cations by attempting to prov ide structure in analysing HRM studies performed in the context of GERD 40 . Most metrics (LES basal pressure, integrated relax ation pressure, distal contractile integral, hiatus hernia size) utilized in reporting oesophageal motor func tion in GERD are readily obtained from oesophageal HRM (FIG. 2) using a standard protocol of ten 5 ml water swallows in the supine position. Furthermore, when oesopha geal peristaltic performance is abnormal, oesophageal body contraction reserve (potential for augmentation of oesophageal body contraction when ineffective oesopha geal motility is found on routine water swallows) can be determined using provocative testing. The simplest provo cative tests consist of either a series of five 2 ml water swallows in rapid succession, termed multiple rapid swallows 41, 42 , or free drinking of 100-150 ml of water from a cup, termed rapid drink challenge 43, 44 . During the series of swallows, inhibition of oesophageal body contraction and relaxation of the LES occurs. Following the final swallow of the sequence, there is augmented oesophageal body contraction and re establishment of LES tone 41, 42 . Augmentation of oesopha geal body contraction is measured as the ratio between distal contractile integral (DCI) following multiple rapid swallows and the mean DCI during standard wet swal lows. Contraction reserve indicates a DCI ratio >1, and enables phenotyping of oesopha geal body peristalsis with implications on management outcome 42, 45 . Absence of contraction reserve is associated with an increased likelihood of transit symptoms ( dysphagia) following a 360° fundoplication 42 . Evaluation and reporting of oesophageal motor func tion in GERD can be achieved through three hierarchical steps, as outlined in the following subsections. The first two steps can reveal abnormalities that can be independ ent of each other; however, the coexistence of abnormal ities might predict an increased likelihood of abnormal oesophageal reflux burden. The final step only applies when oesophageal body motor function is abnormal and as an exploratory tool that might have implications on management outcome.
Integrity of the oesophagogastric junction barrier. EGJ hypomotility is defined as low EGJ resting tone, with end expiratory LES pressure <5 mmHg (REF. 12 ), or EGJ contractile integral <39-47 mmHg per cm . EGJ morphology is based on the relationship between the intrinsic LES and crural diaphragm, and is described as one of the three EGJ subtypes described in the previous section. When the EGJ barrier is intact, the EGJ resting tone is normal and the LES and crural diaphragm are superimposed (EGJ morphology type 1 Oesophageal body contraction reserve. This metric is evaluated when oesophageal body motor function is abnormal. Contraction reserve is present when multiple rapid swallow DCI is higher than the mean wet swal low DCI. For example, the ratio between multiple rapid swallow DCI and wet swallow DCI is >1 (REF. 42 ).
Ambulatory reflux monitoring Proven versus unproven GERD.
Ambulatory reflux monitoring is performed to document oesophageal reflux burden or to define the relationship between symptom events and reflux epi sodes. The most common settings consist of persisting oesophageal symptoms despite seemingly adequate acidsuppressive therapy, such as a failed PPI test or atypical symptoms (chest pain, cough, laryngeal symp toms) that might not directly implicate GERD but could improve with GERD therapy if pathological reflux is present 4, 5 (FIG. 3) . In the typical clinical scenario, ambula tory reflux monitoring has either rulein or ruleout value in defining abnormal oesophageal reflux burden 46 . The concepts of unproven GERD and proven GERD, deliberated extensively and defined here precisely during this consensus process, determine how reflux monitor ing is performed. In the absence of prior evidence of reflux (unproven GERD; with no prior LA classification grade C or D oesophagitis, peptic stricture or Barrett mucosa on endoscopy, or no prior positive ambulatory reflux study), or before antireflux surgery (ARS; for example, Nissen or Toupet fundoplication), testing is performed off antisecretory therapy for 7-10 days 47 . When irrefutable evidence of GERD exists (proven GERD; EGD evidence of LA classification grade C or D oesophagitis, peptic stricture, longsegment Barrett mucosa or prior abnormal ambulatory reflux monitor ing), testing can be performed on antisecretory therapy, in which the objective is to determine if ongoing symp toms can be explained by abnormal oesophageal reflux burden or linked to reflux episodes. In this setting, pH testing alone is insufficient in describing weakly acidic reflux episodes that predominate in patients on PPI ther apy, therefore, pHimpedance testing is used 48 . When reflux monitoring is repeated after ARS or other inva sive reflux therapy, the same testing method used before intervention is performed, typically off anti secretory therapy. If suspicion of GERD is strong in the setting of negative 24 h reflux monitoring, repeated and prolonged monitoring using a wireless pH probe can be considered, as daytoday variation in oesophageal reflux burden has been documented and some patients struggle to eat and behave normally with an oesophageal catheter in place 49 . Repeat testing in this context could improve diagnos tic yield and the finding of abnormal reflux burden can affect management direction 49, 50 . As typical reflux symptoms are initially managed with an empiric PPI trial, persisting symptoms despite PPI therapy can be an indication for ambulatory reflux monitoring (FIG. 3) . However, the PPI trial is not perfect, with a specificity of only 50-60% despite sensitivity of ~80% in predicting erosive oesophagitis or an abnormal pH study 51, 52 . Investigation of persisting reflux symptoms, or alarm symptoms, starts with an EGD with biopsies to exclude alternative mucosal processes, such as infectious oesophagitis or eosinophilic oesophagitis 53 . Persisting symptoms, both typical and atypical, necessitate ambula tory reflux monitoring to determine if antireflux therapy is indicated; the more atypical the symptoms, the greater the need for ambulatory reflux monitoring.
Reflux metrics. Oesophageal acid exposure time (AET)
is the most commonly used metric in defining abnor mal oesophageal reflux burden. AET can be extracted from both pH and pHimpedance studies (FIG. 4) and is calcu lated as the percentage of time that pH is <4.0 in the distal oesophagus (5 cm above the LES) for the duration of the ambulatory study 7, 10 . AET can be separately calcu lated for upright and supine periods. Pathological supine AET can implicate a disrupted EGJ barrier, as TLESRs are generally suppressed during sleep 54 . Symptomreflux association is an essential part of interpretation. This process requires the patient to report symptoms during the ambulatory study, typically using an event monitor button on the reflux monitoring device worn by the patient 55 . Concurrent reflux episodes are identi fied by reflux software using pH drops below 4.0 or impedancedetected retrograde movement of gastric content (FIG. 4) . A symptom event is considered associated with a reflux episode if the symptom occurs within 2 min following the reflux episode 7 . Although AET and symptom reflux association are the two main metrics used in interpreting ambulatory reflux monitoring studies, additional metrics can be extracted, especially when pHimpedance testing is used. Number of reflux episodes is often reported, and impedancedetected reflux episodes are more reliable than those detected based on decreases in pH alone 56 . Proximal oesophageal and pharyngeal reflux monitor ing using pH or impedance sensors is possible; however, this approach has limited value in directing antireflux therapy as symptom outcome cannot be predicted based on these metrics 57, 58 . Baseline mucosal impedance, especially when measured at night when swallow related artefacts are at a minimum (MNBI; mean nocturnal baseline impedance), correlates inversely with AET and can be a marker of abnormal mucosal integrity 59, 60 . The postreflux swallowinduced peristaltic wave (PSPW) is an antegrade impedancedetected bolus propagation reaching all distal impedance monitoring sites within 30 s of a reflux event, and is an assessment of clearance of refluxate that can be measured in patients studied on or off therapy. The PSPW index identifies the pro portion of reflux events followed by PSPW compared with all other reflux events, and can be lower in erosive and nonerosive GERD compared with healthy individ uals as controls 59 . Furthermore, this index might assist in distinguishing hypersensitive oesophagus from functional heartburn 61, 62 .
Interpretation of reflux monitoring Data acquisition. Catheterbased ambulatory reflux monitoring (pH or pHimpedance studies) is performed over a 24 h period, with the distal oesophageal pH sensor positioned 5 cm proximal to the manometrically measured LES. Wireless pH probes are typically posi tioned 6 cm proximal to the squamocolumnar junction during EGD. These single sensor probes can record and transmit distal oesophageal pH data for up to 96 h and are better tolerated than ambulatory catheterbased testing 46 . Catheter or probe placement is performed after an overnight fast and after withholding anti secretory therapy for at least 7 days when testing off PPI is performed. Patients are recommended to maintain normal activities and meals, and keep a diary of meals, symptoms, and recumbency periods 7, 10 .
Analysis of pH data. The key metric extracted from any pH or pHimpedance study is the AET, which requires at least 16 h of recording. Meal times are excluded and the study is scanned visually to identify artefacts, catheter displacement or wireless probe dislodgement that could affect AET calculations. Total AET is con sidered physiological when <4%, as determined from normative studies (TABLE 2) , and pathological when >6%, whereas values in between are borderline and require additional clinical or physiological evidence to confirm GERD [63] [64] [65] [66] [67] [68] [69] [70] . Total, upright and supine AET are separately calculated and reported. When a dual probe pH catheter is used, proximal oesophageal AET can also be reported (FIG. 4b,c) . With wireless pH testing, averaged AET and AET for each day of pH recording are separately available. Specificity increases with aver aged AET, whereas sensitivity is increased with AET from the worst day during the study. AET is margin ally higher with the wireless probe compared with catheter based pH studies, but similar thresholds can be used for both modes of reflux monitoring 49, 71, 72 . AET is considered more statistically valid and reproducible than the composite DeMeester score that takes upright, supine and total AET, longest reflux episode, reflux epi sodes >5 min and the total number of reflux episodes into account 73 .
Symptom reflux association. Episodic symptoms with finite onset and offset can be subject to evaluation of symptom reflux association (FIG. 4d) , whereas continu ous symptoms cannot be assessed by this approach. The dominant or most bothersome symptom is utilized for primary evaluation, secondary symptoms can also be evaluated. A cough detector can count and time cough events; this objective can also be achieved with ambula tory manometry. A simple ratio of associated symptoms to all symptoms defines the symptom index, which is abnormal if >50% 74 . In addition, the number of symp toms should be reported for relevance, as the symptom index can be based on one event only. Symptom associ ation probability (SAP) takes into account 2 min periods with and without reflux episodes and symptom events, and applies a statistical test (Fisher's exact test) on a twobytwo table generated with this data 55 . A P value <0.05 (or SAP >95%) corresponds to a <5% chance that symptoms and reflux episodes could have cooccurred just by chance 55 . A similar conclusion can be reached using the Ghillebert probability estimate, which utilizes posthoc statistical modelling from para meters routinely collected during a pH study to define symptom reflux association 75 . The yield and diagnostic value of symp tom reflux association is highest when many symptoms are recorded, with the patient recording the symptom promptly upon occurrence 76 . Multiple symptoms with the 2min window are counted as a single symptom. Substantial daytoday variability in reflux episodes and in symptom occurrence does occur, but the results of symptom reflux association are reproducible if suffi cient symptom events are observed during the study 77 . Recording of symptoms represents the weakest element in symptom reflux association testing, as incomplete or delayed symptom recording by the patient can render this metric negative and of limited clinical value. Thus, careful instruction and explanation to the patient is essential for success. Nevertheless, when positive, symptom reflux association can augment the evidence that clinically relevant reflux is present and can define reflux hypersensitivity. Evidence for symptom reflux association is considered to be sound when both SAP and the symptom index are positive [78] [79] [80] .
Analysis of impedance data. Impedance monitoring was initially believed to provide improved accuracy of reflux evidence, but impedancebased parameters have generally not been predictive of reflux treatment out comes 81, 82 . Although infrequent reflux episodes (<40) could indicate physiological reflux, there is variability in the association of reflux episodes with oesophageal reflux burden [83] [84] [85] [86] [87] [88] . High numbers of episodes (>80) could suggest pathological reflux burden, whereas border line values (40-80) require alternate reflux evidence.
By contrast, MNBI could provide complementary longi tudinal evidence of oesophageal mucosal damage from reflux exposure. Normative MNBI thresholds have been defined (2,292 Ω), but low values are seen in oesopha geal motility dis orders with impaired clearance and in abnormal oesophageal mucosa (eosinophilic oesophagi tis, Barrett mucosa), which can confound clinical util ity 59, 89 . Nevertheless, erosive and nonerosive GERD are both associated with lower MNBI values than healthy individuals as controls and patients with functional heartburn 90 . Low MNBI values have also been associated with improved medical and surgical outcome, suggest ing relevance in GERD manage ment 60, 91 . MNBI could, therefore, represent a complementary or adjunctive metric, available in all settings in which pHimpedance monitoring is performed. Typical reflux symptoms (heartburn, acid regurgitation) are initially treated with empiric acid suppression in the absence of alarm symptoms (dysphagia, anaemia, weight loss). Endoscopy (with oesophageal biopsy sample to evaluate eosinophilic oesophagitis) is performed if alarm symptoms are present, if symptoms do not respond to empiric acid suppression or if presentation is atypical. If endoscopy is negative, an empiric trial of anti-secretory therapy might be indicated, especially with typical symptoms. Los Angeles (LA) classification grade A or B oesophagitis might be encountered in asymptomatic individuals; ambulatory reflux monitoring will be needed if antireflux surgery is planned. With persisting symptoms without clear explanation, ambulatory reflux monitoring is indicated, in the form of either pH or pH-impedance monitoring performed off acid suppression (unproven GERD). Ambulatory reflux monitoring might also be performed in patients with proven GERD (prior LA classification grade C or D oesophagitis, Barrett mucosa, peptic stricture or reflux evidence on prior ambulatory reflux monitoring) if symptoms persist despite antireflux therapy, whereby the intent is to identify persisting reflux evidence, reflux hypersensitivity or absence of reflux evidence. *If not attempted previously. GERD phenotypes. The metrics described earlier have highest value in predicting reflux outcome when testing is performed off PPI therapy in unproven GERD 81, 82, 92 . Phenotypes with pathological reflux burden on ambula tory reflux monitoring, with or without symptom association, predict the highest likelihood of symptom improvement from antireflux therapy 81, 93 . However, thresholds defining pathological from physiological reflux burden are not precise, and a 'grey area' exists, for example, in borderline reflux burden or inconsistent symptom index and SAP, in which the clinical presenta tion and alternate reflux evidence could complement ambulatory reflux monitoring findings. Symptomatic phenotypes with physiological oesophageal reflux burden can implicate a functional basis for symptoms, whereby symptom improvement is suboptimal with antireflux therapy 38, 93 . Within these phenotypes, reflux hyper sensitivity consists of symptom-reflux association in the setting of physiological reflux burden, whereas functional heartburn or functional chest pain implies a normal ambulatory reflux monitoring study with negative symptom reflux association 38 . Monitoring using pH impedance is also used in proven GERD if symptoms persist, when testing is performed on maximal antisecretory therapy. In these instances, similar AET thresholds can be utilized and the yield of abnormal oesophageal acid burden is expected to be low (typically <1%) 94 . Management decisions will, therefore, need to be based on symptom-reflux associ ation and number of reflux events. Utilizing these para meters, the possible phenotypes prompting escalation of antireflux therapy are as follows (FIG. 3) : inadequate control of oesophageal acid burden with anti secretory therapy; persisting symptoms associated with impedance detected reflux episodes; and abnormally high impedancedetected reflux episodes. By contrast, the following phenotypes could indicate adequate acid control or alternate mechanisms for symptom gener ation: normal (physiological) oesophageal acid burden; lack of association between persisting symptoms and reflux episodes; and low impedancedetected reflux epi sodes. Borderline reflux burden could also be encoun tered in proven GERD with similar implications as in unproven GERD. Additionally, reflux hyper sensitivity or functional symptoms could overlap with true GERD. Under all these circumstances, clinical presentation and evidence from other tests for GERD evaluation will need to be combined with results from ambulatory reflux monitoring in planning management.
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Other tests for evaluation of GERD Several questionnaires with varying characteristics have been developed for the assessment of GERD 95 . A few of these have some diagnostic utility and two have been valid ated in multiple languages: the Reflux Disease Question naire (RDQ) and the GERDQ [95] [96] [97] . However, both have shown only modest accuracy (~65-70%) for symptombased diagnosis of GERD and, therefore, cannot be recommended as standalone diagnostic instruments 96, 97 . Endoscopy has high specificity but very low sensi tivity for GERD diagnosis, as oesophageal mucosa is normal in up to 70% of patients with symptomatic GERD 98, 99 . When performed following recent or current antisecretory therapy, the probability of a normal assess ment increases to 90% 100 . Thus, endoscopy has very low In all instances, arrows point to reflux episodes. a | Acid reflux episodes on pH-impedance monitoring. The pH electrode is positioned 5 cm above the lower esophageal sphincter (LES), and the impedance electrodes at 3 cm, 5 cm, 9 cm, 11 cm, 15 cm and 17 cm above the LES, stacked with the most proximal electrode at the top. Note the abrupt drop in the tracing designated pH, and drop in impedance recordings (arrows). b | Distal oesophageal acid reflux episodes on dual-channel pH monitoring, with pH electrodes 15 cm apart, and the distal electrode 5 cm above the LES. Note the drop in pH (arrow) limited to the bottom (distal) tracing only. c | Prolonged reflux events with delayed clearance in both distal and proximal channels on dual-channel pH monitoring. Note the pH drop in both distal and proximal tracings (arrows), and persistent low pH following the drop, especially in the bottom (distal) tracing. d | Weakly acidic and acidic reflux episodes associated with symptom events (symptoms occurring within 2 min of reflux episodes) on pH-impedance monitoring. The first reflux episode consists of drops in impedance recordings without a prominent drop in pH (arrow), indicating that this is a weakly acidic reflux episode. The second episode consists of drops in both pH and impedance (arrow), indicating that this is an acid reflux episode. Vertical lines indicate when the patient reported symptoms. sensitivity for initial GERD diagnosis, and is appropriate only in the presence of alarm symptoms, such as dys phagia or unintentional weight loss, multiple risk factors for Barrett oesophagus (>50 years of age, male sex, pro longed reflux symptoms, obesity) or failure to respond to appropriate antisecretory therapy 6 . Supplemental endo scopic tools such as narrowband imaging and confocal laser endomicroscopy provide limited additional benefit in identifying mucosal damage consistent with reflux. Their use remains restricted to research given intrinsic limita tions such as high costs, timeconsuming proce dures and weak interobserver and intraobserver agree ment. Furthermore, there is higher clinical value with reflux monitoring than these newer tools 101 . Novel endo scopic probes for measurement of oesophageal mucosal impedance have been introduced, providing basal mucosal impedance estimates similar to that obtained from ambulatory pHimpedance monitoring [102] [103] [104] [105] . These tools have shown promise in distinguishing reflux disease from functional oesophageal disorders and in monitor ing treatment response. Future studies will determine the true potential of these methods as diagnostic tools 106 .
Oesophageal biopsies evaluating histological changes potentially related to reflux, such as dilated inter cellular spaces, basal cell hyperplasia and papillary elongation, have shown moderate to good sensitivity and specifi city in identifying GERD [107] [108] [109] [110] . When findings are considered collectively as evidence of microscopic oesophagitis, particularly when combined into a global severity score, distinction of erosive oesophagitis and nonerosive reflux disease from functional heartburn and healthy individuals is possible with good accur acy 111, 112 . Furthermore, some studies suggest useful ness of histological findings in monitoring response to medical and surgical therapies 112, 113 . Conversely, there are several drawbacks, mainly related to limited specifi city and interobserver and/or intraobserver agreement between pathologists 114 . These restrictions limit the usefulness of histological assessment in current clin ical practice, although efforts are ongoing to resolve these limitations 114 .
The use of barium radiography in diagnosing GERD is not recommended. Data comparing radio graphic diagnosis of GERD with that from reflux test ing demonstrate that radiographic findings do not correlate with the prevalence or extent of reflux seen on ambulatory pH impedance monitoring 115 . Thus, barium radio graphy alone cannot be used to diagnose GERD, although radiography can be accurate and useful in defining EGJ anatomy.
The use of impedance planimetry to measure cross sectional area and distensibility at the EGJ (endolumi nal functional lumen imaging probe or endoFLIP) has shown no demonstrable value in the diagnostic workup of GERD, although clinical data are scant 116, 117 . Similarly, not enough evidence currently exists to recommend the clinical use of salivary pepsin in the diagnosis of GERD.
Oesophageal function testing implications GERD phenotypes can be defined on the basis of clin ical assessment, endoscopy and oesophageal function testing. The best use of GERD phenotypes lies in pre dicting outcomes from management, thereby enabling practitioners to choose the most ideal management options to maximize therapeutic outcome. In this regard, symptoms and PPI response do not adequately pheno type GERD into reliable therapeutic categories. Limited research is available describing prediction of therapy outcomes on the basis of presentation, morphology of the EGJ and oesophageal motor function.
Using EGD findings, GERD can be phenotyped into erosive and nonerosive disease, with clearly better symptomatic outcomes from PPI therapy in erosive GERD than nonerosive disease. For erosive GERD, LA classification grades C and D provide the most con sistent evidence of GERD 8, 118 . LA classification grade B oesophagitis also prompts medical management with acid suppression 8 ; however, this grade might not be suffi cient evidence for a recommendation of ARS in the absence of alternate phenotypic GERD evidence. LA classification grade A oesophagitis is frequently encoun tered in asymptomatic healthy volunteers and does not provide conclusive evidence for GERD 119 . Evidence of reflux on ambulatory reflux monitor ing prompts initiation or escalation of acidsuppressive therapy (FIG. 3) , and pathological AET is a predictor of good outcome from both medical and ARS therapy 81, 92, 93 . Within abnormal AET cohorts, those with positive symptom-reflux association (FIG. 4d) have the highest likelihood of improvement from antireflux therapy [78] [79] [80] . Thus, the GERD phenotype with the strongest evidence consists of pathological AET associated with positive symptom-reflux association, especially if both SAP and symptom index are positive 80, 93 . Antacids and algin ates can treat infrequent or breakthrough reflux symp toms 120 . Baclofen, a γaminobutyric acid type B receptor agonist, can reduce reflux events by inhibiting TLESRs, with potential adjunctive symptomatic benefit when this drug is available 121 . ARS might be a consideration that can be explored in some patients, especially when EGJ dis ruption is documented. By contrast, physiological AET with no symptom-reflux association predicts suboptimal outcomes from antireflux therapy and can overlap with functional oesophageal syndromes. Coexisting functional syndromes (functional dyspepsia, IBS) might also predict suboptimal outcome from antireflux therapy 122, 123 and might prompt treatment with neuromodulators 38 . Reflux hypersensitivity (physiological acid burden with positive symptom-reflux association) represents a challenge in interpretation and management. The preva lence of reflux hypersensitivity is higher when pH imped ance is employed for reflux monitoring compared with pH monitoring alone 124 . When symptom-reflux association is recorded with impedancedetected reflux events, anti reflux management approaches (including ARS) might be successful, especially if evidence for EGJ disruption and/or hiatus hernia exists 125, 126 . Although true acid sensi tivity (symptom associated with pHdetected reflux events alone) is relatively rare, this occurrence is associated with suboptimal response to antireflux therapy 125 and treat ments similar to those for functional oesophageal syn dromes (for example, neuromodulators) might provide a better outcome than with antireflux therapy alone 38 .
Conditions mimicking GERD
Of patients referred with refractory reflux symptoms, at least 30% have functional heartburn, rumination syn drome or achalasia rather than GERD 127 (TABLE 1) . In the achalasia spectrum disorders, retrosternal discomfort and regurgitation occur as a consequence of oesopha geal outflow obstruction rather than from reflux 127, 128 .
Within patients referred for ARS, ~1% are diagnosed with achalasia by oesophageal HRM, and an additional 1.5% have evidence of EGJ outflow obstruction 26 . The diagnosis of achalasia and EGJ outflow obstruction have profound clinical importance, as invasive management for these conditions (EGJ disruption) is contradictory to that performed in GERD (EGJ enhancement with ARS).
Rumination syndrome consists of voluntary contrac tion of abdominal wall musculature during periods of crural diaphragm relaxation, leading to a sharp increase in intraabdominal pressure that forces gastric content through the oesophagus into the mouth 129 . This increase in intraabdominal pressure can be identified in the form of an 'r' wave on prolonged HRM with impedance in the postprandial period. Ambulatory pHimpedance monitor ing, however, does not discriminate a rumination episode from a reflux episode 130, 131 . Supragastric belching starts with air forced into the oesophagus by contraction of the diaphragm, creating negative pressure in the oesophagus, followed by con traction of abdominal and thoracic muscles resulting in immediate expulsion in the form of a belch 131 . Less com monly, air is swallowed into the stomach and expelled out by a mechanism similar to rumination. In addi tion to careful history and clinical observation, supra gastric belching can be identified on concurrent HRM with impedance.
Oesophageal symptoms can be associated with condi tions such as eosinophilic oesophagitis, lichen planus and infectious oesophagitis (oesophageal candidiasis, herpes simplex oesophagitis, cytomegalovirus oesophagitis). Finally, functional disease can give rise to any oesopha geal symptom, including symptoms similar to GERD 38 . Ambulatory reflux monitoring demonstrates physio logical reflux parameters, but minor motor disorders and contractionwave abnormalities on HRM are compatible with functional oesophageal disorders 38 .
Conclusions
Combining existing data on reflux testing with expert consensus opinion, this Consensus Statement describes the modern evaluation of GERD, especially when oesopha geal symptoms persist despite empiric anti secretory therapy and when EGD does not identify an alternate mechanism for symptoms. In this setting, HRM identifies motor pathophysiology conducive to gastro esophageal reflux and ambulatory reflux monitoring describes pathological oesophageal reflux burden and symptom-reflux association. Other novel parameters on pH testing or pHimpedance testing, including MNBI and the PSPW index, might complement conventional reflux para meters in improving confidence for a reflux diagno sis. In the future, understanding GERD pathophysio logy in more detail, particularly the inter relationship between GERD and oesophageal motor dysfunction, and evaluat ing oesophageal reflux burden with novel metrics could help identify GERD phenotypes better and improve manage ment outcomes
. A need now exists for prospective and collaborative outcome studies to deter mine the clinical value of oesophageal function testing in predicting symptomatic outcome.
Box 3 | Open research questions
• Understanding mechanisms of pathological acid reflux in terms of abnormalities of oesophageal and oesophagogastric junction structure and function, including the acid pocket • Clarification as to whether pathological acid reflux is the cause of abnormal oesophageal motor function, or if reflux is the consequence of abnormal motor function in GERD • Exploration of the clinical utility of existing and novel oesophageal physiological metrics from high-resolution manometry and ambulatory reflux monitoring in identifying GERD phenotypes that predict GERD management outcome • Elucidation of the importance of oesophageal sensitivity as a mechanism for GERD symptom reporting and a potential target for treatment
